KBP Bioscience, a clinical stage biotechnology company based in Princeton, announced on Monday it has appointed Nick Hart as chief financial officer.
Hart, who has more than 30 years of experience in financial and operational leadership within the health care sector, most recently serving as the CFO at Temptime Corp.
“Nick’s impressive record and breadth of financial leadership experience, which includes work at both public and private companies, makes him an extremely valuable addition to the KBP team at a pivotal juncture for the Company,” Thijs Spoor, CEO of KBP Biosciences, said. “Nick is well equipped to help us navigate the next phase of the Company’s growth as we work to complete the Phase 2b study of our lead product candidate, KBP-5074, for the treatment of uncontrolled hypertension in chronic kidney disease patients.”
From 2008 to 2013, Hart served as the CFO and acting president at HemCon Medical Technologies. Previously, he was CFO of Alltracel Pharmaceuticals. Earlier in his career, he worked at venture capital firms Porton Capital Ltd. and Bioscience Managers Ltd. He also spent time at LSE and Cantab Phamaceuticals.
“I am excited to join KBP at such a crucial time and grateful to the Board for their confidence,” Hart said. “Until now, late-stage CKD patients with uncontrolled hypertension had few safe and viable treatment options. Our goal with KBP-5074 is to bring a new first-in-class therapy to these patients and address a major unmet medical need. I am looking forward to working with the KBP team to continue advancing this great initiative.”
